Answers are grounded in this paper and cite their sources.
Ubrogepant and atogepant are oral calcitonin gene-related peptide receptor antagonists used for acute and preventive migraine treatment, respectively. Prospective real-world evidence from healthcare settings remains limited. This prospective, multicenter, observational cohort study enrolled adults with migraine across nine sites in Israel (June 2023 to January 2026). Participants initiated ubrogepant (UBRO cohort) or atogepant (ATO cohort), with medication and dose per physician decision, completing baseline and 3-month assessments. The primary endpoint was the proportion of patients reporting being satisfied or extremely satisfied with treatment at Month 3. Secondary outcomes included changes in the Headache Impact Test (HIT-6) score, monthly headache days (MHDs), and acute medication use days for the ATO cohort; and Migraine Treatment Optimization Questionnaire (MTOQ-6) score and 2-hour pain relief/pain freedom reported in an electronic diary (e-Diary) during the first 30 days for the UBRO cohort. Of 154 enrolled patients, 149 initiated treatment. In the ATO cohort, 63 of 69 (91.3%) treated patients completed Month 3 assessments (mean age 42.7 ± 13.5 years, 84.1% female); 66.7% reported satisfaction with the treatment. Mean MHDs and acute medication use days decreased from baseline by 5.7 days ( p < 0.001) and 4.5 days ( p = 0.004), respectively. Mean HIT-6 score decreased from baseline by 11.6 points ( p < 0.001); the proportion of patients reporting severe headache impact decreased from 96.8% at baseline to 58.1% at Month 3. In the UBRO cohort, 75 of 80 (93.8%) treated patients completed Month 3 follow-up (mean age 46.4 ± 14.6 years, 92.0% female); 54.7% reported satisfaction. Among e-Diary completers ( n = 57), on average per participant, 64.1% of headache days were treated with ubrogepant, with 52.6% of ubrogepant-treated headache days resulting in pain relief and 25.8% resulting in pain freedom at 2 hours post-dose. At Month 3, mean MTOQ-6 score improved from baseline by a mean of 2.7 points ( p < 0.001). Adverse events (AEs) were infrequent (17.4% in ATO and 10.0% in UBRO), with zero serious AEs. Both atogepant and ubrogepant were associated with substantial patient-reported benefits and were generally well tolerated over 3 months, supporting their integration into routine migraine management. ClinicalTrials.gov, NCT05827887. Registered 13 April 2023.
No takes yet. Share an insight, caveat, or question.
Lev et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: